Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs offers a comprehensive portfolio of cutting-edge anti-CSF3R recombinant antibodies, backed by validated supporting data and first-class technical support, compatible with a wide range of immunology applications. These high-performance antibodies are engineered to be highly accurate and specific, ensuring researchers have greater efficiency in gaining insights into CSF3R pathogenicity and developing therapeutics.
The granulocyte colony-stimulating factor receptor (GCSFR), also known as CSF3R or CD114, is an important regulator of granulopoiesis. Recent research suggests that it is overexpressed in a variety of cancer types, where it promotes tumor growth by affecting both myeloid and non-myeloid immune cells. Given its relevance in carcinogenesis, GCSFR is a promising therapeutic target for the development of novel anticancer medicines.
Colony-stimulating factor 3 receptor; GCSFR; G-CSF-R; G-CSF Receptor; granulocyte colony-stimulating factor receptor; CD114; Cluster of Differentiation 114; SCN7.
The protein encoded by this gene is the receptor for colony-stimulating factor 3, a cytokine that controls the production, differentiation, and function of granulocytes. The encoded protein, which is a member of the family of cytokine receptors, may also function in some cell surface adhesion or recognition processes. Alternatively, spliced transcript variants have been described. Mutations in this gene are a cause of Kostmann syndrome, also known as severe congenital neutropenia.
Creative Biolabs provides a comprehensive range of recombinant antibodies specifically designed to precisely target CSF3R. These versatile antibodies, available in multiple formats, exhibit exceptional specificity and affinity, making them ideal for a wide array of experimental techniques. By leveraging our advanced antibody engineering and production capabilities, we offer researchers high-quality tools to delve deeper into the intricate role of CSF3R in various biological processes, facilitating groundbreaking discoveries in the fields of immunology, oncology, and beyond.
Table 1. Featured anti-CSF3R recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
MOB-0140CT | Recombinant Mouse anti-Human CSF3R Monoclonal antibody (MNN886) | Human | Mouse | FC |
MOB-1808z | Mouse Anti-CSF3R Recombinant Antibody (clone 28F2) | Human | Mouse IgG1 | WB, ELISA, FC, IHC |
MOR-0829 | Hi-Affi™ Rabbit Anti-CSF3R Recombinant Antibody (clone DS829AB) | Human | Rabbit IgG | WB, FC |
HPAB-0081-YJ | Mouse Anti-CSF3R Recombinant Antibody (clone LMM-741) | Human | Mouse IgG1, κ | FC, IP, WB |
NEUT-549CQ | Rat Anti-Csf3r Recombinant Antibody (clone CBL638) | Mouse | Rat IgG2b | Neut |
Creative Biolabs is a leading biotechnology company focused on producing novel and effective therapeutic treatments. Our team of experts leverages cutting-edge technology and advanced research techniques to deliver customized solutions for a wide range of applications. We are always committed to quality and ensuring that every product meets the highest quality and performance requirements.
Creative Biolabs employs advanced genetic engineering techniques to produce customized antibodies that specifically target the CSF3R protein. This innovative approach enables the efficient synthesis of high-quality antibodies, ensuring a consistent and reliable supply to meet diverse research and development needs.
Featured Anti-CSF3R Recombinant Antibody Production Platforms
Fig.1 Milligram-scale anti-CSF3R recombinant antibody production.
Fig.2 Gram-scale anti-CSF3R recombinant antibody production.
Creative Biolabs provides a comprehensive selection of recombinant antibodies targeting CSF3R, offering researchers a versatile toolbox for their specific experimental needs. These antibodies are available in a variety of forms, allowing versatility and adaptability for a wide range of applications.
Fig.3 Full-length anti-CSF3R recombinant antibody production and modalities.
Table 2. Public drug targeting CSF3R.
Company | Research Phase | Classification | Condition |
Adello Biologics (Originator) Amneal Pharmaceuticals Kashiv Biosciences |
Launched - 2022 |
Follow-on Products Granulocyte Colony-Stimulating Factor (G-CSF) Polypeptides, from 41 AA Recombinant proteins |
Neutropenia |
Hanmi (Originator) Spectrum Pharmaceuticals |
Launched - 2022 |
Fc Fusion Proteins Granulocyte Colony-Stimulating Factor (G-CSF) Polypeptides, from 41 AA |
Cancer, breast Cytopenia, chemotherapy- or radiotherapy-induced Neutropenia |
Accord Healthcare (Originator) | Launched - 2015 |
Biosimilars Follow-on Products Granulocyte Colony-Stimulating Factor (G-CSF) Polypeptides, from 41 AA Recombinant proteins |
Neutropenia |
Fuji Pharma (Originator) Kidswell Bio (Originator) Mochida |
Launched - 2013 |
Colony-Stimulating Factors (CSF) Follow-on Products Polypeptides, from 41 AA Recombinant proteins |
Neutropenia |
Hospira (Pfizer) Pfizer (Originator) |
Launched - 2010 |
Biosimilars Follow-on Products Granulocyte Colony-Stimulating Factor (G-CSF) Polypeptides, from 41 AA Recombinant proteins |
Acute radiation syndrome Bone marrow and stem cell transplantation Neutropenia Neutropenia, febrile |
Hexal (Originator) Sandoz (Originator) Sawai |
Launched - 2009 |
Biosimilars Follow-on Products Granulocyte Colony-Stimulating Factor (G-CSF) Polypeptides, from 41 AA Recombinant proteins |
Bone marrow and stem cell transplantation Neutropenia Transplantation, bone marrow |
BioGeneriX CT Arzneimittel (Originator) Nippon Kayaku ratiopharm (Originator) Teva (Originator) |
Launched - 2008 |
Biosimilars Follow-on Products Granulocyte Colony-Stimulating Factor (G-CSF) Polypeptides, from 41 AA Recombinant proteins |
Bone marrow and stem cell transplantation Cytopenia, chemotherapy- or radiotherapy-induced Neutropenia |
Dr Reddy's Laboratories (Originator) Dr. Reddy's Laboratories (Dr Reddy's Laboratories) |
Launched - 2001 |
Granulocyte Colony-Stimulating Factor (G-CSF) Polypeptides, from 41 AA Recombinant proteins |
Agranulocytosis Neutropenia |
Kyowa Hakko Kirin (Kyowa Kirin) Kyowa Hakko (Kyowa Kirin) Kyowa Kirin (Originator) Yakult Honsha |
Launched - 1994 |
Granulocyte Colony-Stimulating Factor (G-CSF) Polypeptides, from 41 AA Recombinant proteins |
Agranulocytosis |
Almirall Chugai (Chugai Pharmaceutical) Chugai Pharmaceutical (Originator) Sanofi |
Launched - 1991 |
Granulocyte Colony-Stimulating Factor (G-CSF) Polypeptides, from 41 AA Recombinant proteins |
Acute myeloid leukemia Anemia Neutropenia |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
As a leader in antibody research, Creative Biolabs is dedicated to developing innovative antibody solutions for cancer therapy. Our anti-CSF3R recombinant antibodies, engineered for optimal performance, offer researchers powerful tools to investigate CSF3R's role in cancer progression. Contact us today to find out more about our goods and how they may help you with your study.